We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
Read MoreHide Full Article
Key Takeaways
BMY will give Eliquis free to Medicaid and donate more than 7 tons of its active ingredient.
Eliquis is Bristol Myers Squibb's top drug, posting $11B in sales in the first nine months of 2025.
The government deal grants BMY three years of tariff relief and no future pricing mandates.
Bristol Myers Squibb (BMY - Free Report) announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the active pharmaceutical ingredient (API) used in Eliquis to help ensure supply-chain resilience.
Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation, a type of irregular heartbeat, not caused by a heart valve problem.
BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer (PFE - Free Report) for Eliquis.
The drug is one of the most widely prescribed oral blood thinner.
While the financial impact of the deal was not provided by BMY, Eliquis is the top revenue generator for the company.
Eliquis sales totaled $11 billion in the first nine months of 2025, up 8% year over year.
Hence, it remains to be seen how the pricing deal will impact sales of its top-revenue generator next year.
The pricing deal with the government also includes offering drugs like Sotyktu (deucravacitinib), Zeposia (ozanimod), Reyataz (atazanavir), Baraclude (entecavir), and Orencia SC (abatacept) at 80% discount to cash-paying patients.
BMY will continue to expand domestic production across the United States.
On the other hand, BMY will receive three years of tariff relief and will not be subject to future pricing mandates.
BMY’s Growth Portfolio, comprising drugs like Opdivo, Opdivo Qvantig, Reblozyl, Breyanzi, Camzyos and Opdualag, among others, has somewhat stabilized its revenue base amid generic competition for its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane).
Competition for BMY’s Top Drugs
Johnson & Johnson’s (JNJ - Free Report) Xarelto is also a Factor Xa inhibitor, similar to Eliquis.
However, JNJ is facing patent challenges for Xarelto in the United States. JNJ co-developed Xarelto with Bayer AG.
Apart from Eliquis, immuno-oncology drug Opdivo is another top revenue generator for BMY.
While the recent label expansions of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for more than 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive the long-term growth of Keytruda.
BMY’s Price Performance, Valuation & Estimates
Shares of Bristol Myers have lost 5.3% in a year against the industry’s growth of 15.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 9.07x forward earnings, higher than its mean of 8.40x but lower than the large-cap pharma industry’s 17.27x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved north in the past 60 days, while that for 2026 EPS has moved south.
Image: Shutterstock
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
Key Takeaways
Bristol Myers Squibb (BMY - Free Report) announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the active pharmaceutical ingredient (API) used in Eliquis to help ensure supply-chain resilience.
Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation, a type of irregular heartbeat, not caused by a heart valve problem.
BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer (PFE - Free Report) for Eliquis.
The drug is one of the most widely prescribed oral blood thinner.
While the financial impact of the deal was not provided by BMY, Eliquis is the top revenue generator for the company.
Eliquis sales totaled $11 billion in the first nine months of 2025, up 8% year over year.
Hence, it remains to be seen how the pricing deal will impact sales of its top-revenue generator next year.
The pricing deal with the government also includes offering drugs like Sotyktu (deucravacitinib), Zeposia (ozanimod), Reyataz (atazanavir), Baraclude (entecavir), and Orencia SC (abatacept) at 80% discount to cash-paying patients.
BMY will continue to expand domestic production across the United States.
On the other hand, BMY will receive three years of tariff relief and will not be subject to future pricing mandates.
BMY’s Growth Portfolio, comprising drugs like Opdivo, Opdivo Qvantig, Reblozyl, Breyanzi, Camzyos and Opdualag, among others, has somewhat stabilized its revenue base amid generic competition for its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane).
Competition for BMY’s Top Drugs
Johnson & Johnson’s (JNJ - Free Report) Xarelto is also a Factor Xa inhibitor, similar to Eliquis.
However, JNJ is facing patent challenges for Xarelto in the United States. JNJ co-developed Xarelto with Bayer AG.
Apart from Eliquis, immuno-oncology drug Opdivo is another top revenue generator for BMY.
While the recent label expansions of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck’s (MRK - Free Report) blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for more than 50% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive the long-term growth of Keytruda.
BMY’s Price Performance, Valuation & Estimates
Shares of Bristol Myers have lost 5.3% in a year against the industry’s growth of 15.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY’s shares currently trade at 9.07x forward earnings, higher than its mean of 8.40x but lower than the large-cap pharma industry’s 17.27x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has moved north in the past 60 days, while that for 2026 EPS has moved south.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.